An open‐label, investigator‐initiated, single‐center, prospective, pilot clinical study to evaluate the efficacy of a skin whitening serum applied twice daily combined with a spot‐preventing SPF50+ sunscreen in healthy female subjects with melasma hyperpigmentation

• Published in: Journal of cosmetic dermatology Vol. 21; no. 4; pp. 1523 - 1532
• Main Authors: Cantelli, Mariateresa, Ferrillo, Maria, Granger, Corinne, Fabbrocini, Gabriella
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 01.04.2022
• Subjects: 4‐n‐butylresorcinol; Adult; dipotassium glycyrrhizate; Female; glycolic acid; Humans; Hyperpigmentation - drug therapy; Hyperpigmentation - etiology; Hyperpigmentation - prevention & control; Melanosis - diagnosis; Melanosis - drug therapy; melasma; niacinamide; Original Contributions; Pilot Projects; Prospective Studies; Skin Care; Skin Lightening Preparations - chemistry; Skin Lightening Preparations - therapeutic use; Sunscreening Agents - adverse effects; Treatment Outcome; niacinamide; melasma; 4-n-butylresorcinol; dipotassium glycyrrhizate; glycolic acid
• ISSN: 1473-2130; 1473-2165; 1473-2165
• DOI: 10.1111/jocd.14271

Background Melasma is a common skin disorder characterized by alterations in normal skin pigmentation. The objective was to evaluate the efficacy and safety of a skin whitening serum containing niacinamide, hydroxyphenoxy propionic acid, dipotassium glycyrrhizate, glycolic acid, and 4‐n‐butylresorci...